Lupin’s margin pain: what’s causing it, and is there a balm to soothe it?

[ad_1]

While the company has a good pipeline of products for the US market and is taking measures to reduce costs, investors’ confidence in the company’s execution capabilities has taken a beating, and regaining trust will not be easy. The US drug regulator’s warning on the company’s plants has made the going all the more tougher.

[ad_2]

Source link